دورية أكاديمية
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
| العنوان: | Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis |
|---|---|
| المؤلفون: | Ouyang,Jingzhong, Wang,Zhengzheng, Yuan,Kun, Yang,Yi, Zhou,Yanzhao, Li,Qingjun, Yang,Nanmu, Zhao,Haitao, Zhao,Hong, Zhou,Jinxue |
| بيانات النشر: | Dove Press |
| سنة النشر: | 2023 |
| المجموعة: | Dove Medical Press |
| مصطلحات موضوعية: | Journal of Hepatocellular Carcinoma |
| الوصف: | Jingzhong Ouyang,1,* Zhengzheng Wang,1,* Kun Yuan,2,* Yi Yang,3,4 Yanzhao Zhou,1 Qingjun Li,1 Nanmu Yang,1 Haitao Zhao,5 Hong Zhao,3,4 Jinxue Zhou1 1Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, People’s Republic of China; 2School of Public Health, Capital Medical University, Beijing, People’s Republic of China; 3Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 4Key Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 5Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hong Zhao, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100020, People’s Republic of China, Email zhaohong@cicams.ac.cn Jinxue Zhou, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450003, People’s Republic of China, Email zhoujx888@126.comPurpose: To evaluate the efficacy and safety of lenvatinib plus programmed death-1 (PD-1) antibody as postoperative adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risks of recurrence.Patients and Methods: A series of 137 patients with HCC at high risks of recurrence who underwent hepatectomy at our hospital between October 2019 and January ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/adjuvant-lenvatinib-plus-pd-1-antibody-for-hepatocellular-carcinoma-wi-peer-reviewed-fulltext-article-JHCTest |
| الإتاحة: | https://doi.org/10.2147/JHC.S424616Test https://www.dovepress.com/adjuvant-lenvatinib-plus-pd-1-antibody-for-hepatocellular-carcinoma-wi-peer-reviewed-fulltext-article-JHCTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5A9C8870 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |